Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Simpson Website

R. Mark Simpson, D.V.M., Ph.D.

Selected Publications

1)  Wei BR, Simpson RM.
Digital pathology and image analysis augment biospecimen annotation and biobank quality assurance harmonization.
Clin. Biochem. 47: 274-9, 2014.
[Journal]
2)  Ramos-Vara JA, Webster JD, Dusold D, Miller MA.
Immunohistochemical Evaluation of the Effects of Paraffin Section Storage on Biomarker Stability.
Vet. Pathol. 51: 102-9, 2014.
[Journal]
3)  Prieto DA, Johann DJ, Wei BR, Ye X, Chan KC, Nissley DV, Simpson RM, Citrin DE, Mackall CL, Linehan WM, Blonder J.
Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens.
Biomark Med. 8: 269-86, 2014.
[Journal]
4)  Simpson RM, Bastian BC, Michael HT, Webster JD, Prasad ML, Conway CM, Prieto VM, Gary JM, Goldschmidt MH, Esplin DG, Smedley RC, Piris A, Meuten DJ, Kiupel M, Lee CC, Ward JM, Dwyer JE, Davis BJ, Anver MR, Molinolo AA, Hoover SB, Rodriguez-Canales J, Hewitt SM.
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma.
Pigment Cell Melanoma Res. 27: 37-47, 2014.
[Journal]
5)  Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA.
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
Mol Oncol. 8: 261-72, 2014.
[Journal]
6)  Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, Hoover S, Simpson RM, Simmons J, Gary J, Snapper CM, Casellas R, Mock BA.
B Cell-Specific Deficiencies in mTOR Limit Humoral Immune Responses.
J. Immunol. 191: 1692-703, 2013.
[Journal]
7)  Bakhsheshian J, Wei BR, Chang KE, Shukla S, Ambudkar SV, Simpson RM, Gottesman MM, Hall MD.
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Proc. Natl. Acad. Sci. U.S.A. 110: 20801-6, 2013.
[Journal]
8)  Risinger JI, Custer M, Feigenbaum L, Mark Simpson R, Hoover SB, Webster JD, Chandramouli GV, Tessarollo L, Barrett JC.
Normal viability of Kai1/Cd82 deficient mice.
Mol. Carcinog. [Epub ahead of print], 2013.
[Journal]
9)  Stuelten CH, Cervoni-Curet FN, Busch JI, Sutton E, Webster JD, Kavalukas SL, Wakefield LM, Barbul A, Niederhuber JE.
SDF-1a Mediates Wound-Promoted Tumor Growth in a Syngeneic Orthotopic Mouse Model of Breast Cancer.
PLoS ONE. 8: e60919, 2013.
[Journal]
10)  Zhang M, Ju W, Yao Z, Yu P, Wei B, Simpson RM, Waitz R, Fassò M, Allison JP, Waldmann TA.
Augmented IL-15Ralpha Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice.
J Immunol. 188: 6156-64, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/16/2014.